Plasma Lipidomic Profiles of Kidney, Breast, and Prostate Cancer Patients Differ from Healthy Controls
- Publicado
- Servidor
- Research Square
- DOI
- 10.21203/rs.3.rs-734203/v1
Early cancer screening is one of the unmet needs in clinical medicine. The peripheral blood analysis is a preferred method for efficient population screening as blood collection is well embedded in clinical practice and minimally invasive for patients. Lipids are important biomolecules, and variations in lipid concentrations may reflect pathological disorders. The lipidomic profiling by ultrahigh-performance supercritical fluid chromatography hyphenated to mass spectrometry of human plasma for distinguishing samples obtained from breast, kidney, and prostate cancer patients and healthy controls is investigated. The mean sensitivity, specificity, and accuracy of the new lipidomic profiling approach were 85%, 95%, and 92% for kidney cancer; 91%, 97%, and 94% for breast cancer; and 87%, 95%, and 92% for prostate cancer. No association of statistical models with tumor stage is observed. The statistically most significant lipid species for differentiation of studied cancer types are CE 16:0, Cer 42:1, LPC 18:2, PC 36:2, PC 36:3, SM 32:1, and SM 41:1.